RPG Life Sciences Q4 Revenue Jumps 23.6% to Rs 176.9 Cr
Mumbai: RPG Life Sciences Limited has reported a 23.6% year-on-year increase in revenue for the fourth quarter of FY26, along with a strong EBITDA margin of 25.6%, while also recommending a final dividend of 300% for the financial year ended March 31, 2026.
The company’s revenue from operations stood at Rs. 176.9 crore in Q4 FY26 compared to Rs. 143.1 crore in the same period last year, reflecting robust growth and improved operational performance. For the full financial year FY26, revenue rose to Rs. 707.5 crore from Rs. 653.4 crore in FY25, marking an 8.3% increase with a healthy EBITDA margin of 24.4%.
The Domestic Formulations (DF) business, which contributes nearly 70% of total sales, recorded a strong growth of 18.2% in Q4, significantly outperforming the Indian Pharma Market growth of 10.1%. For the full year, the DF segment delivered a 13.7% growth compared to the market growth of 8.6%, driven by strong performance across key therapy segments including nephrology, oncology, and pain management.
The company also highlighted a strong recovery in its Active Pharmaceutical Ingredient (API) division, which registered a remarkable growth of 144.3% in Q4 FY26. This rebound comes after the restoration of operations following a fire incident at its API manufacturing facility in January 2025.
Commenting on the performance, Managing Director Ashok Nair said the company has built solid momentum through improved field effectiveness, operational discipline, and a focused approach on key brands. He added that the resilience shown by the API business reflects the strength of the company’s operations and teams.
According to RPG Life Sciences Limited, the company plans to strengthen its product pipeline, enhance brand equity, and expand its presence in fast-growing global markets.
The Board of Directors has recommended a final dividend of Rs. 24 per equity share, representing 300% on the face value of Rs. 8 per share, subject to shareholder approval.
RPG Life Sciences is a research-based pharmaceutical company engaged in branded formulations, global generics, and synthetic APIs, with a strong presence in both domestic and international markets.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.